Insider Selling: Opiant Pharmaceuticals Inc (OPNT) Insider Sells 1,821 Shares of Stock

Share on StockTwits

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) insider Phil Skolnick sold 1,821 shares of Opiant Pharmaceuticals stock in a transaction dated Monday, November 5th. The shares were sold at an average price of $18.01, for a total value of $32,796.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Phil Skolnick also recently made the following trade(s):

  • On Thursday, October 4th, Phil Skolnick sold 4,778 shares of Opiant Pharmaceuticals stock. The shares were sold at an average price of $18.32, for a total value of $87,532.96.

NASDAQ:OPNT opened at $16.34 on Wednesday. The stock has a market capitalization of $52.58 million, a P/E ratio of 5.56 and a beta of 0.34. Opiant Pharmaceuticals Inc has a 52-week low of $12.75 and a 52-week high of $36.77.

Opiant Pharmaceuticals (NASDAQ:OPNT) last released its earnings results on Thursday, August 9th. The technology company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.55. The business had revenue of $3.15 million for the quarter, compared to the consensus estimate of $2.10 million. Opiant Pharmaceuticals had a negative return on equity of 471.43% and a negative net margin of 449.52%. Research analysts expect that Opiant Pharmaceuticals Inc will post -4.7 EPS for the current year.

A number of research firms recently issued reports on OPNT. Cantor Fitzgerald set a $42.00 target price on Opiant Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, October 4th. ValuEngine downgraded Opiant Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, July 28th.

An institutional investor recently bought a new position in Opiant Pharmaceuticals stock. Northern Trust Corp purchased a new position in shares of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 24,372 shares of the technology company’s stock, valued at approximately $350,000. Northern Trust Corp owned about 0.86% of Opiant Pharmaceuticals as of its most recent SEC filing. 4.51% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Opiant Pharmaceuticals Inc (OPNT) Insider Sells 1,821 Shares of Stock” was reported by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Recommended Story: The Discount Rate – What You Need to Know

Insider Buying and Selling by Quarter for Opiant Pharmaceuticals (NASDAQ:OPNT)

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply